Oxyntomodulin: The Dual-Acting Gut Peptide That Could Outperform GLP-1 Drugs for Weight Loss

Oxyntomodulin (OXM) is a gut-derived peptide that acts as a dual agonist of both the GLP-1 receptor and the glucagon receptor. This review summarizes evidence that OXM injections in humans cause significant reductions in weight and appetite while increasing energy expenditure — a combination that single GLP-1 receptor agonists don't fully achieve. Although glucagon receptor activation normally raises blood sugar (potentially harmful in diabetics), the simultaneous GLP-1 receptor activation counteracts this effect. In diet-induced obese mice, OXM improved glucose tolerance. The dual agonist approach may offer enhanced weight loss and better glycemic control compared to GLP-1 agonists alone.

This is a narrative review article synthesizing published research on oxyntomodulin's pharmacology, including human injection studies, mouse models of diet-induced obesity, and receptor binding data. No new experimental data were generated.

This review foreshadowed the dual and multi-agonist drugs now in development (like survodutide and other GLP-1/glucagon dual agonists). It laid out the scientific rationale for why combining GLP-1 and glucagon receptor activity could be more effective for obesity and diabetes than targeting GLP-1 alone — an idea that has since driven a major wave of pharmaceutical development.

This 2012 review was ahead of its time. The concept it describes — dual receptor agonism for metabolic disease — has since become one of the hottest areas in drug development. Tirzepatide (a GLP-1/GIP dual agonist) became a blockbuster, and several GLP-1/glucagon dual agonists (like survodutide and mazdutide) are now in clinical trials. Oxyntomodulin itself served as the natural proof of concept that the body already uses multi-receptor peptide signaling to regulate metabolism.

As a review article, this does not present new experimental data. The human evidence for OXM cited was based on relatively small, short-term injection studies. The clinical translation of dual agonism was still theoretical at the time of publication, with no approved dual-agonist drugs available.